British Investor Considers Rescue of Troubled Genetics Firm 23andMe

A British investor with significant holdings in 23andMe is reportedly interested in a potential rescue of the beleaguered Californian consumer genetics company. Richard Magides, director of Singapore-based Zentree Investment, holds a 9.6 per cent stake in the firm and is positioned as the second-largest shareholder following its recent filing for bankruptcy protection in the United States.

Magides has expressed a willingness to back additional funding to facilitate a turnaround, provided certain issues are addressed. He remains optimistic about the company’s future, suggesting that with the right changes, 23andMe could be valued at over one billion dollars. This positive outlook comes despite the company’s struggles to generate consistent revenue and profitability, which culminated in its recent bankruptcy filing.

Founded in 2006 by Anne Wojcicki, the former wife of Google co-founder Sergey Brin, 23andMe has become a prominent name in the DNA-testing sector. The firm offers home saliva-testing kits that produce personalised genetic reports covering health and ancestry”

Having attracted substantial investment in the past, including a significant equity injection from GSK, 23andMe faced escalating challenges related to cash burn and management practices. The company’s inability to convert its robust customer base into sustainable revenue streams has now put its future in jeopardy.

The bankruptcy process raises pressing concerns regarding customer data privacy, especially under the spectre of new ownership. As the market responds to the news, state attorneys general have urged customers to delete their data, prompting fluctuating interest in the firm’s offerings.

Magides acknowledges the brand may have lost some luster but believes in the inherent value of the company’s product and data. He emphasises the potential advances in artificial intelligence combined with genetic data could lead to significant breakthroughs in the future.

While the pathway to recovery remains fraught with uncertainty, the interest from key stakeholders like Magides may provide a glimmer of hope for 23andMe and its customers.